|
1
|
D’Addario G, Pintilie M, Leighl NB, et al:
Platinum-based versus non-platinum-based chemotherapy in advanced
non-small-cell lung cancer: a meta-analysis of the published
literature. J Clin Oncol. 23:2926–2936. 2005.PubMed/NCBI
|
|
2
|
Ohe Y, Ohashi Y, Kubota K, et al:
Randomized phase III study of cisplatin plus irinotecan versus
carboplatin plus paclitaxel, cisplatin plus gemcitabine, and
cisplatin plus vinorelbine for advanced non-small-cell lung cancer:
Four-Arm Cooperative Study in Japan. Ann Oncol. 18:317–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schiller JH, Harrington D, Belani CP, et
al: Comparison of four chemotherapy regimens for advanced
non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002.
View Article : Google Scholar
|
|
4
|
Belani CP, Ramalingam S, Perry MC, et al:
Randomized, phase III study of weekly paclitaxel in combination
with carboplatin versus standard every-3-weeks administration of
carboplatin and paclitaxel for patients with previously untreated
advanced non-small-cell lung cancer. J Clin Oncol. 26:468–473.
2008. View Article : Google Scholar
|
|
5
|
Socinski MA, Ivanova A, Bakri K, et al: A
randomized phase II trial comparing every 3-weeks
carboplatin/paclitaxel with every 3-weeks carboplatin and weekly
paclitaxel in advanced non-small cell lung cancer. Ann Oncol.
17:104–109. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Quoix E, Zalcman G, Oster JP, et al:
Carboplatin and weekly paclitaxel doublet chemotherapy compared
with monotherapy in elderly patients with advanced non-small-cell
lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet.
378:1079–1088. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hirabayashi M, Endoh K, Teramachi M, et
al: Phase II study of carboplatin and weekly paclitaxel combination
chemotherapy in advanced non-small cell lung cancer: a Kansai
Clinical Oncology Group study. Lung Cancer. 44:355–362. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shitara K, Matsuo K, Oze I, et al:
Meta-analysis of neutropenia or leukopenia as a prognostic factor
in patients with malignant disease undergoing chemotherapy. Cancer
Chemother Pharmacol. 68:301–307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kishida Y, Kawahara M, Teramukai S, et al:
Chemotherapy-induced neutropenia as a prognostic factor in advanced
non-small-cell lung cancer: results from Japan Multinational Trial
Organization LC00-03. Br J Cancer. 101:1537–1542. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Di Maio M, Gridelli C, Gallo C, et al:
Chemotherapy-induced neutropenia and treatment efficacy in advanced
non-small-cell lung cancer: a pooled analysis of three randomised
trials. Lancet Oncol. 6:669–677. 2005.PubMed/NCBI
|
|
11
|
Pallis AG, Agelaki S, Kakolyris S, et al:
Chemotherapy-induced neutropenia as a prognostic factor in patients
with advanced non-small cell lung cancer treated with front-line
docetaxel-gemcitabine chemotherapy. Lung Cancer. 62:356–363. 2008.
View Article : Google Scholar
|
|
12
|
Mountain CF: Revisions in the
International System for Staging Lung Cancer. Chest. 111:1710–1717.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sobin L and Wittekind CH: TNM
Classification of Malignant Tumours. 6th edition. Wiley-Liss; New
York, NY: pp. 99–103. 2002
|
|
14
|
National Cancer Institute (NCI): Common
Terminology Criteria for Adverse Events (CTCAE) version 4.0. May
28–2009, http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
Accessed October 9, 2012.
|
|
15
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
16
|
Jiang H, Tao W, Zhang M, Pan S, Kanwar JR
and Sun X: Low-dose metronomic paclitaxel chemotherapy suppresses
breast tumors and metastases in mice. Cancer Invest. 28:74–84.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Komuta K, Osaki T, Mori M, et al: A phase
II study directed by a clinical pathway for carboplatin and weekly
paclitaxel in previously untreated patients with unresectable
non-small cell lung cancer. Chemotherapy. 56:39–45. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sakakibara T, Inoue A, Sugawara S, et al:
Randomized phase II trial of weekly paclitaxel combined with
carboplatin versus standard paclitaxel combined with carboplatin
for elderly patients with advanced non-small-cell lung cancer. Ann
Oncol. 21:795–799. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Browder T, Butterfield CE, Kräling BM, et
al: Antiangiogenic scheduling of chemotherapy improves efficacy
against experimental drug-resistant cancer. Cancer Res.
60:1878–1886. 2000.PubMed/NCBI
|
|
20
|
Drevs J, Fakler J, Eisele S, et al:
Antiangiogenic potency of various chemotherapeutic drugs for
metronomic chemotherapy. Anticancer Res. 24:1759–1763.
2004.PubMed/NCBI
|
|
21
|
Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han
LY, Lin YG and Sood AK: Metronomic chemotherapy enhances the
efficacy of antivascular therapy in ovarian cancer. Cancer Res.
67:281–288. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Katsumata N, Yasuda M, Takahashi F, et al:
Dose-dense paclitaxel once a week in combination with carboplatin
every 3 weeks for advanced ovarian cancer: a phase 3, open-label,
randomised controlled trial. Lancet. 371:1331–1338. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shaked Y, Emmenegger U, Man S, et al:
Optimal biologic dose of metronomic chemotherapy regimens is
associated with maximum antiangiogenic activity. Blood.
106:3058–3061. 2005. View Article : Google Scholar : PubMed/NCBI
|
